Cervicogenic headache and onabotulinumtoxinA: Where do we stand?

Cephalalgia

Volumn 31, Issue 9, 2011, Pages 979-980

  Becker, W J ^a   Chitsantikul, P ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; ONABOTULINUMTOXIN A; UNCLASSIFIED DRUG;

CERVICOGENIC HEADACHE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; EDITORIAL; HEADACHE; HUMAN; NECK MUSCLE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

BOTULINUM TOXINS, TYPE A; FEMALE; HUMANS; MALE; NEUROMUSCULAR AGENTS; POST-TRAUMATIC HEADACHE;

EID: 80052005742     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102411410086     Document Type: Editorial

References (16)

1. Linde M, Hagen K, Salvesen O, Bruvik Gravdahl G, Helde G, Stovner LJ. Onabotulinum toxin A treatment of cervicogenic headache: a randomised, double-blind, placebo-controlled crossover study. Cephalalgia. 2011 ;:
2. Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010 ; 30: 793-803
3. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010 ; 30: 804-814
4. Becker WJ. Cervicogenic headache: evidence that the neck is a pain generator. Headache. 2010 ; 50: 699-705
5. Bartsch T, Goadsby PJ. Increased responses in trigeminocervical nociceptive neurons to cervical input after stimulation of the dura mater. Brain. 2003 ; 126: 1801-1813 (Pubitemid 36917339)
6. Bartsch T, Goadsby PJ. Stimulation of the greater occipital nerve induces increased central excitability of dural afferent input. Brain. 2002 ; 125: 1496-1509 (Pubitemid 34755165)
7. Govind J, King W, Bailey B, Bogduk N. Radiofrequency neurotomy for the treatment of third occipital headache. J Neurol Neurosurg Psychiatry. 2003 ; 74: 88-93 (Pubitemid 36069042)
8. Cooper G, Bailey B, Bogduk N. Cervical zygapophysial joint pain maps. Pain Med. 2007 ; 8: 344-353 (Pubitemid 47039418)
9. Freund BJ, Schwartz M. Treatment of chronic cervical-associated headache with botulinum toxin A: a pilot study. Headache. 2000 ; 40: 231-236 (Pubitemid 30169888)
10. Hobson DE, Gladish DF. Botulinum toxin injection for cervicogenic headache. Headache. 1997 ; 37: 253-255 (Pubitemid 27215348)
11. Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache. 2004 ; 44: 35-42
12. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004 ; 107: 125-133 (Pubitemid 38058707)
13. Gazerani P, Au S, Dong X, Kumar U, Arendt-Nielsen L, Cairns BE. Botulinum neurotoxin type A (BoNTA) decreases the mechanical sensitivity of nociceptors and inhibits neurogenic vasodilation in a craniofacial muscle targeted for migraine prophylaxis. Pain. 2010 ; 151: 606-616
14. Wiegand H, Wellhöner HH. The action of botulinum A neurotoxin on the inhibition by antidromic stimulation of the lumbar monosynaptic reflex. Naunyn-Schmiedeberg's Arch Pharmacol. 1977 ; 298: 235-238 (Pubitemid 8140643)
15. Wiegand H, Erdmann G, Wellhöner HH. I125 labelled botulinum A neurotoxin: Pharmacokinetics in cats after intramuscular injection. Naunyn-Schmiedeberg's Arch Pharmacol. 1976 ; 292: 161-165
16. Habermann E. I125 labeled neurotoxin from clostridium botulinum A: preparation, binding to synaptosomes and ascent to the spinal cord. Naunyn-Schmiedeberg's Arch Pharmacol. 1974 ; 281: 47-56